Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP2C9 polymorphism influence on NSAID pharmacokinetics using saliva samples
RBR-38jcm9Recruiting
- Sponsor
- Faculdade de Odontologia de Bauru
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of naproxen, celecoxib and meloxicam, sponsored by Faculdade de Odontologia de Bauru. Primary endpoints: Salivary pharmacokinetic assessment of naproxen, Salivary pharmacokinetic assessment of celecoxib and 2 more. Started Apr 2019; status: recruiting.
02
Drugs
naproxencelecoxibmeloxicam
Beyond the preview
Go deeper on RBR-38jcm9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-38jcm9.